Released Mar 15, 2023, before the open
10-K filed Mar 15, 2023, 74 days after period end · 0001171843-23-001691
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$11.59M-$11.59M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$12,888,000N/M
Operating Cash Flowderived-$10,641,000N/M
Free Cash Flowderived-$10,695,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Net Income | -$11.59M | -$12.98M | -$8.39M | -$11.68K |
| EPS Diluted | — | — | — | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR